Skip to content

TTRX TTRX Other income, net (Note 6)

Other income, net (Note 6) at other companies

Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$20K-110%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.92M+68.7%
PVL
Palvella TherapeuticsPVLA
-$32K-114%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-$87K-7.4%
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
$38K+1,800%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M
Total equity$6.1M+647%
Total assets$18.6M

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M

Returns & leverage

See full
Return on equity-118.8%
Debt / equity
Current ratio2.2×

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's other income, net (note 6)?
TTRX (TTRX) reported other income, net (note 6) of $5.58K in Q1 2026.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.